News & Updates
The latest news and updates from companies in the WLTH portfolio.
X Energy (XE) Joins Project Prometheus As Founding Partner In AI Nuclear Push
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. * X-Energy (NasdaqGS:XE) has been named a founding member of Project Prometheus, a new AI-driven partnership focused on advanced nuclear deployment. * The company joins Tier 1 partners including Idaho National Laboratory, NVIDIA, and AWS in this government-backed initiative. * Project Prometheus is intended to apply AI tools across nuclear design, licensing, construction, and operations. X-Energy is known for its work on advanced nuclear technologies. Project Prometheus places the company alongside major technology and research partners. For investors tracking NasdaqGS:XE, this move links the company more closely with efforts to apply AI to nuclear development, an area that is gaining attention as countries look for low carbon power options. The Prometheus partnership may influence how X-Energy allocates resources across product development, digital tools, and collaboration with public sector partners. For readers following the stock, the project is likely to become a reference point when assessing the company's role in AI-enabled nuclear projects and how it positions itself in upcoming bids, partnerships, or pilot deployments. Stay updated on the most important news stories for X-Energy by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on X-Energy. We've flagged 3 risks for X-Energy. See which could impact your investment. Quick Assessment * ✅ Price vs Analyst Target: X-Energy trades at US$16.45 versus an analyst target of US$37.86, which is around 56% below the consensus level. * ❌ Simply Wall St Valuation: Shares are flagged as trading about 33% above the platform's estimated fair value. * ❌ Recent Momentum: The stock is down 18.4% over the past 30 days. There's only one way to know the right time to buy, sell or hold X-Energy. Head to Simply Wall St's company report for the latest analysis of X-Energy's Fair Value. Key Considerations * 📊 Project Prometheus ties X-Energy directly to AI driven nuclear deployment work, and this may become a key part of how investors frame its long term story. * 📊 Watch how this partnership feeds into contract wins, funding announcements, and any updates to revenue forecasts or capital needs. * ⚠️ Current losses and less than one year of cash runway highlight financing risk if Prometheus related projects take time to translate into cash flows. Dig Deeper For the full picture including more risks and rewards, check out the complete X-Energy analysis. Alternatively, you can check out the community page for X-Energy to see how other investors believe this latest news will impact the company's narrative.
Oklo, X-Energy Join $200 Million Federal Nuclear Push For AI: Bloomberg
Bloomberg reports that reactor developers Oklo and X-energy are joining a $200 million Trump administration-led program designed to speed new nuclear power plants for artificial intelligence data centers. Details could be announced Wednesday at a Department of Energy AI energy summit. Microsoft and Nvidia are also involved in the previously announced initiative, while several DOE national laboratories and the University of Texas at Austin are slated to share $60 million over three years, according to a document seen by Bloomberg. "Among the goals of the latest initiative are steep reductions in time needed to design, license and build new plants, as well as cuts in the number of staff needed to run them" X-energy jumped as much as 12% after hours, while Oklo gained as much as 9.9%. The program reportedly targets steep reductions in the time and workforce required to design, license, build and operate reactors. It would join a rapidly expanding federal nuclear support stack: * Westinghouse fleet program: At least $80 billion of aggregate project value for new AP1000 reactors, with the government arranging financing and facilitating approvals. * US-Japan partnership: Up to $40 billion of Japanese-backed investment for GE Vernova Hitachi BWRX-300 projects in Tennessee and Alabama. * Gen III+ SMRs: $800 million in cost-shared DOE awards, split between TVA's BWRX-300 project and Holtec's SMR-300 project. * Reactor Pilot Program: An expedited DOE authorization pathway for 11 initial projects, with developers responsible for project costs. * Advanced Reactor Demonstration Program: Roughly $3.2 billion in federal cost-share commitments for TerraPower's Natrium and X-energy's Xe-100 demonstrations. Compared with those capital-heavy programs, the new $200 million effort appears aimed at a different choke point: potentially using AI, federal labs and industry partnerships to compress the paperwork and engineering timelines standing between reactor designs and power-hungry data centers.
Ark Invest doubles down on SpaceX with $52m weekly buying spree
Cathie Wood's Ark Invest has increased its exposure to SpaceX with purchases worth about $52.1 million during the week ended July 10, while cutting positions in semiconductor, streaming and genomics companies as it continued adjusting its portfolios. According to Ark Invest's latest weekly trading disclosure, Space Exploration Technologies Corp. (SPCX) received the firm's largest allocation by value across multiple exchange-traded funds. The investment manager also bought shares of Eli Lilly, Meta Platforms, X-Energy, Coinbase Global and Circle Internet Group, alongside several healthcare, artificial intelligence and defence-related companies. Across individual funds, Ark added SpaceX shares to ARKK, ARKQ, ARKW and ARKX. The latest filings also showed fresh purchases of X-Energy across three ETFs, while Block, Kratos Defense & Security Solutions, Oklo, Pony AI, Kodiak AI and WeRide were among other additions. In healthcare, the firm increased positions in companies including Ionis Pharmaceuticals, Beam Therapeutics, Prime Medicine, Alamar Biosciences, Compass Pathways, and Recursion Pharmaceuticals. Ark continues buying SpaceX after earlier dip purchases The latest trades extend Ark's recent buying activity in SpaceX after several purchases made during the stock's post-listing decline. Last month, the investment firm bought about $32.5 million worth of SpaceX shares after the stock dropped more than 16% from its post-IPO peak. The purchase followed an even larger investment of roughly $444.3 million made across four ETFs on the company's Nasdaq debut on June 12. Ark had also held exposure to SpaceX before its public listing through the ARK Venture Fund, where the aerospace company ranked as the fund's largest holding. Earlier this month, Cathie Wood told Fox Business that SpaceX held a "10-year lead" over competitors, while Ark's internal valuation models projected a base-case enterprise value of about $2.5 trillion by 2030 and a bull-case estimate of approximately $3.1 trillion. Meanwhile, the latest portfolio changes showed the firm reducing holdings in Advanced Micro Devices, Roku, Robinhood Markets, Deere, and Iridium Communications. The disclosures also listed sales of several genomics companies, including Natera, Illumina, Twist Bioscience, 10x Genomics and BioNTech, alongside smaller reductions in Personalis, Absci and Strata Critical Medical. The changes come ahead of the second-quarter earnings season, with the latest disclosures indicating continued portfolio rebalancing across Ark's actively managed funds. The recent buying activity also follows a pattern seen in previous weeks. On June 26, Ark increased its holdings in Coinbase, Circle, Bullish, and Robinhood after all four stocks declined during the trading session. Earlier in June, the firm also purchased about $18.4 million worth of Coinbase shares after the crypto exchange had fallen nearly 13% over the preceding month. Ark manages its exchange-traded funds under a policy that limits any single holding to no more than 10% of a portfolio. The firm periodically adjusts positions to keep those weightings within its target allocations as share prices change.
Cathie Wood's ARK sees major moves in Coinbase and SpaceX stocks By Investing.com
Cathie Wood's ARK ETF published their daily trades for Friday, July 10th, 2026, revealing significant activity in the tech and biotech sectors. Leading the day's trades, ARK made a substantial purchase of 116,971 shares of Space Exploration Technologies Corp (SPCX), with a total dollar value of $17,798,307. This marks a continuation of ARK's interest in the aerospace giant, following a consistent buying pattern over the past week. In another major move, ARK acquired 87,409 shares of Coinbase Global Inc (NASDAQ:COIN) across its ARKK, ARKW, and ARKF ETFs, amounting to $13,849,081. This purchase indicates ARK's ongoing confidence in the cryptocurrency exchange platform, as it follows recent acquisitions earlier in the week. On the selling side, ARK offloaded 19,540 shares of Advanced Micro Devices Inc (NASDAQ:AMD) through its ARKK, ARKQ, and ARKX ETFs, totaling $10,682,908. This sale continues a trend of reducing its position in AMD, with significant shares sold throughout the week. ARK also sold 158,592 shares of 10X Genomics Inc (NASDAQ:TXG) from its ARKK ETF, totaling $6,835,315, and 45,625 shares of Roku Inc (NASDAQ:ROKU), amounting to $6,399,362. These sales suggest a shift in ARK's focus within the genomics and streaming sectors. In the biotech space, ARK added 293,106 shares of Prime Medicine, Inc (NASDAQ:PRME) through its ARKG ETF, with a total investment of $1,239,838, continuing its recent accumulation of the stock. Additionally, ARK purchased 54,804 shares of Generate Biomedicines Inc (GENB) for $861,518, and 28,276 shares of Tempus AI Inc (TEM) for $1,738,974, reflecting its interest in innovative biotech companies. Other notable trades include the sale of 11,092 shares of Deere & Co (NYSE:DE) for $6,576,446 and the acquisition of 137,071 shares of X-Energy Inc (XE) for $2,275,378, highlighting ARK's diverse investment strategy across various sectors. These trades underscore Cathie Wood's ARK Invest's strategic adjustments within its portfolios, reflecting both confidence in emerging technologies and a reevaluation of existing positions. Investors will be closely watching ARK's next moves as it navigates the evolving market landscape. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Cathie Wood's ARK sells AMD stock, buys SpaceX and X-Energy By Investing.com
Cathie Wood's ARK ETF published their daily trades for Tuesday, July 7th, 2026, shedding light on significant moves across its portfolio. The most notable transaction was the purchase of 607,567 shares of X-Energy Inc (NASDAQ:XE) through its ARKK ETF, ARKQ ETF, and ARKX ETF, totaling $11,130,627. This continues a trend from previous days, showing ARK's growing interest in X-Energy. In a substantial sell, ARK offloaded 8,667 shares of Advanced Micro Devices Inc (NASDAQ:AMD) through its ARKK ETF, amounting to $4,784,617. This sale follows a pattern, as ARK sold 15,576 shares of AMD the previous day, indicating a potential shift in strategy regarding this stock. ARK also made a significant purchase of 44,196 shares of Space Exploration Technologies Corp (SPCX) through its ARKK ETF, with a total value of $7,089,922. This marks a considerable addition to their holdings, emphasizing ARK's bullish stance on SpaceX. Another notable buy was 6,354 shares of Eli Lilly and Co (NYSE:LLY) via the ARKG ETF, valued at $7,625,181, highlighting ARK's interest in the pharmaceutical sector. On the selling front, ARK divested 44,330 shares of BioNTech SE (NASDAQ:BNTX) from its ARKG ETF, totaling $4,163,916. This follows a broader trend of reducing positions in biotech firms. ARK's ARKG ETF also saw the sale of 72,323 shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT), valued at $1,554,944, and 39,151 shares of CareDx Inc (NASDAQ:CDNA), worth $1,137,728, further reflecting a strategic shift in the biotech space. Meanwhile, ARK increased its stake in Compass Pathways PLC (NASDAQ:CMPS) by acquiring 191,070 shares through the ARKG ETF, amounting to $2,453,338, suggesting confidence in the potential of mental health therapeutics. Additionally, ARK continued to invest in Generate Biomedicines Inc (GENB) with the purchase of 44,170 shares through the ARKG ETF, valued at $747,356, following previous buys in recent days. Finally, ARK sold 40,787 shares of Illumina Inc (NASDAQ:ILMN) across its ARKK and ARKG ETFs, and 20,992 shares of Natera Inc (NASDAQ:NTRA), totaling $5,957,529, showing a consistent pattern of reducing exposure to these genomics companies. These trades illustrate ARK's dynamic investment strategy, balancing between high-conviction buys and strategic sales to optimize its portfolio in the ever-evolving market landscape. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.